CannaPharmaRX (OTC: CPMD) adds debtholder repayment schedules update

Rhea-AI Filing Summary

CannaPharmaRX, Inc. entered into letter agreements that set out payment schedules to address outstanding amounts owed to two significant debtholders. The company states that these schedules are intended to manage existing debt, avoid additional defaults, and still retain capital to grow operations and deliver product. The agreements and their terms had already been described in the company’s quarterly report for the period ended June 30, 2025, but the actual schedule documents were mistakenly omitted. This report is being used to file those repayment schedule agreements as exhibits so they are formally included in the public record.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001081938false00010819382025-08-072025-08-07iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2025

CannaPharmaRX, Inc.

(Exact name of registrant as specified in its charter)

Delaware		333-251016		27-4635140
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Suite 3600, 888—3rd Street SW

Calgary, Alberta, Canada T2P 5C5

(Address of principal executive offices, including zip code)

(949) 652-6838

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CPMD		OTC Markets

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 8.01 Other Events.

CannaPharmaRX, Inc. ("the "Company") entered into letter agreements with payment schedules to address outstanding amounts due to two significant debtholders of the Company. The Company is entering into the payment schedule as a way to address outstanding debts and avoid additional defaults but retain capital to continue to grow operations and deliver product. Information about the payment schedules was previously included in the Company’s 10Q for period ending June 30, 2025, however, the actual schedule agreements were erroneously not included. The Company is filing this 8-k to include the actual payment schedule agreement that were erroneously not included in the exhibits of the Company’s 10Q for period ending June 30, 2025.

Item 9.01 Financial Statements and Exhibits.

The repayment schedules for the debtholders are being attached as an exhibit herewith.

Exhibit No.		Description
1.1		Letter Agreement (Payment Schedule) - A. Tal Payment Schedule (Payment Schedule) - Koze Investments
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				CANNAPHARMARX, INC.
October 3, 2025				By:	/s/ Constantine Nkafu
				Name:	Constantine Nkafu
				Title:	CEO

3

FAQ

What did CannaPharmaRX, Inc. (CPMD) disclose in this 8-K?

CannaPharmaRX, Inc. disclosed that it has entered into letter agreements establishing payment schedules with two significant debtholders and is filing the actual repayment schedule agreements as exhibits that were previously omitted from its quarterly report for the period ended June 30, 2025.

Why did CannaPharmaRX, Inc. arrange payment schedules with debtholders?

The company states it is entering into these payment schedules to address outstanding debts, avoid additional defaults, and still retain enough capital to continue growing operations and delivering product.

How does this 8-K relate to CannaPharmaRX, Inc.’s June 30, 2025 10-Q?

Information about the payment schedules was already included in the June 30, 2025 quarterly report, but the actual schedule agreements were erroneously not attached as exhibits. This 8-K is being used to file those payment schedule agreements.

Who are the debtholders referenced by CannaPharmaRX, Inc. in the payment schedules?

The exhibit list references a letter agreement payment schedule for A. Tal and a payment schedule for Koze Investments, which are identified as debtholders of the company.

What exhibit did CannaPharmaRX, Inc. add in connection with these payment schedules?

The company added a letter agreement covering the payment schedule for A. Tal and a payment schedule for Koze Investments as an exhibit, along with the cover page interactive data file embedded within the Inline XBRL document.

Does this 8-K describe any new financing or just documentation of existing arrangements for CannaPharmaRX, Inc.?

The disclosure explains that the payment schedules were already described in the earlier quarterly report and that this 8-K is being filed to include the actual schedule agreements that were previously omitted from the exhibits.